Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.

Core Evid · 2007 · PMC3012552 · PMID 21221196

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

When disease progression was assessed by the IRF the addition of high-dose bevacizumab to carboplatin/paclitaxel chemotherapy was shown to prolong time to progression compared with carboplatin/paclitaxel alone, although this difference failed to reach statistical significance (7.0 vs 5.9 months).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.